With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven ma
Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh